Study concludes that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after treatment
Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantation
Anti-GBM antibody disease, also known as Goodpasture's disease, is a severe autoimmune disease where the immune system mistakenly develops IgG-antibodies directed against the glomerular basement membrane (GBM), resulting in an acute immune attack causing severe kidney injury and, in some patients, also injuring the lungs.
Anti-GBM is a rare and acute immunological disease with a significant unmet medical need that affects approximately 1.5 in a million people annually, with a majority of patients losing their kidney function and requiring chronic dialysis and kidney transplantation. In severe cases, anti-GBM antibody disease may lead to death.
The first high-level data read out has been completed and the encouraging results indicate that imlifidase treatment may lead to increased renal survival in patients with anti-GBM antibody disease due to rapid clearance of IgG antibodies. The phase 2 anti-GBM study enrolled 15 subjects, six females and nine males with a median age of 61 years of age (range 19-79 years) recruited across centers from five European countries, including
At inclusion, ten of the patients were dialysis dependent, including five that were oliguric/anuric, while five patients were dialysis independent but had eGFR levels below 15 ml/min. Six hours after imflidase no patient had anti-GBM antibody levels above the normal range.
At six months, ten patients were dialysis independent (median eGFR 27 ml/min). Four patients were dialysis dependent, while one patient had died (unrelated to imlifidase treatment). The safety profile of imlifidase in the population was concluded as being favourable.
"The positive results from the phase 2 trial suggest the potential for treatment and thereby the opportunity to increase the chances of renal survival in difficult to treat patients with anti-GBM disease", says Sponsor and Coordinating Principle Investigator,
"We are very encouraged by the positive outcome from the phase 2 trial in anti-GBM antibody disease. Anti-GBM is the first IgG-mediated disease outside transplantation, where imlifidase has been shown to stop an immunologic attack. This marks an important milestone in
This is information that
For further information, please contact:
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com
About
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharm-announces-positive-high-level-data-from-investigator-initiated-phase-2-trial-with-iml,c3202826
https://mb.cision.com/Main/1219/3202826/1310647.pdf
(c) 2020 Cision. All rights reserved., source